29 results on '"Velden, V.H. van der"'
Search Results
2. Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group.
- Author
-
Kern, W., Westers, Theresia M., Bellos, F., Bene, M.C., Bettelheim, P., Brodersen, L.E., Burbury, K., Chu, S.C., Cullen, M., Porta, M.D., Dunlop, A.S., Johansson, U., Matarraz, S., Oelschlaegel, U., Ogata, K., Porwit, A., Preijers, F.W., Psarra, K., Saft, L., Subirá, D., Weiß, E., Velden, V.H. van der, Loosdrecht, A. van de, Kern, W., Westers, Theresia M., Bellos, F., Bene, M.C., Bettelheim, P., Brodersen, L.E., Burbury, K., Chu, S.C., Cullen, M., Porta, M.D., Dunlop, A.S., Johansson, U., Matarraz, S., Oelschlaegel, U., Ogata, K., Porwit, A., Preijers, F.W., Psarra, K., Saft, L., Subirá, D., Weiß, E., Velden, V.H. van der, and Loosdrecht, A. van de
- Abstract
01 januari 2023, Item does not contain fulltext, BACKGROUND: Myelodysplastic syndromes (MDS) represent a diagnostic challenge. This prospective multicenter study was conducted to evaluate pre-defined flow cytometric markers in the diagnostic work-up of MDS and chronic myelomonocytic leukemia (CMML). METHODS: Thousand six hundred and eighty-two patients with suspected MDS/CMML were analyzed by both cytomorphology according to WHO 2016 criteria and flow cytometry according to ELN recommendations. Flow cytometric readout was categorized 'non-MDS' (i.e. no signs of MDS/CMML and limited signs of MDS/CMML) and 'in agreement with MDS' (i.e., in agreement with MDS/CMML). RESULTS: Flow cytometric readout categorized 60% of patients in agreement with MDS, 28% showed limited signs of MDS and 12% had no signs of MDS. In 81% of cases flow cytometric readouts and cytomorphologic diagnosis correlated. For high-risk MDS, the level of concordance was 92%. A total of 17 immunophenotypic aberrancies were found independently related to MDS/CMML in ≥1 of the subgroups of low-risk MDS, high-risk MDS, CMML. A cut-off of ≥3 of these aberrancies resulted in 80% agreement with cytomorphology (20% cases concordantly negative, 60% positive). Moreover, >3% myeloid progenitor cells were significantly associated with MDS (286/293 such cases, 98%). CONCLUSION: Data from this prospective multicenter study led to recognition of 17 immunophenotypic markers allowing to identify cases 'in agreement with MDS'. Moreover, data emphasizes the clinical utility of immunophenotyping in MDS diagnostics, given the high concordance between cytomorphology and the flow cytometric readout. Results from the current study challenge the application of the cytomorphologically defined cut-off of 5% blasts for flow cytometry and rather suggest a 3% cut-off for the latter.
- Published
- 2023
3. Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet.
- Author
-
Velden, V.H. van der, Preijers, F.W., Johansson, U., Westers, Theresia M., Dunlop, A., Porwit, A., Béné, M.C., Valent, P., Marvelde, J. Te, Wagner-Ballon, O., Oelschlaegel, U., Saft, L., Kordasti, S., Ireland, R., Cremers, E., Alhan, C., Duetz, C., Hobo, W.A., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenshink-Brodersen, L., Font, P., Loken, M.R., Matarraz, S., Ogata, K., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Porta, M.G. Della, Burbury, K., Bellos, F., Weiß, E., Kern, W., Loosdrecht, A. van de, Velden, V.H. van der, Preijers, F.W., Johansson, U., Westers, Theresia M., Dunlop, A., Porwit, A., Béné, M.C., Valent, P., Marvelde, J. Te, Wagner-Ballon, O., Oelschlaegel, U., Saft, L., Kordasti, S., Ireland, R., Cremers, E., Alhan, C., Duetz, C., Hobo, W.A., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenshink-Brodersen, L., Font, P., Loken, M.R., Matarraz, S., Ogata, K., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Porta, M.G. Della, Burbury, K., Bellos, F., Weiß, E., Kern, W., and Loosdrecht, A. van de
- Abstract
01 januari 2023, Item does not contain fulltext, BACKGROUND: Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. METHODS: Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. RESULTS: We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. CONCLUSIONS: These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.
- Published
- 2023
4. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group.
- Author
-
Porwit, A., Béné, M.C., Duetz, C., Matarraz, S., Oelschlaegel, U., Westers, Theresia M., Wagner-Ballon, O., Kordasti, S., Valent, P., Preijers, F.W., Alhan, C., Bellos, F., Bettelheim, P., Burbury, K., Chapuis, N., Cremers, E., Porta, M.G. Della, Dunlop, A., Eidenschink-Brodersen, L., Font, P., Fontenay, M., Hobo, W., Ireland, R., Johansson, U., Loken, M.R., Ogata, K., Orfao, A., Psarra, K., Saft, L., Subira, D., Marvelde, J. Te, Wells, D.A., Velden, V.H. van der, Kern, W., Loosdrecht, A.A. van de, Porwit, A., Béné, M.C., Duetz, C., Matarraz, S., Oelschlaegel, U., Westers, Theresia M., Wagner-Ballon, O., Kordasti, S., Valent, P., Preijers, F.W., Alhan, C., Bellos, F., Bettelheim, P., Burbury, K., Chapuis, N., Cremers, E., Porta, M.G. Della, Dunlop, A., Eidenschink-Brodersen, L., Font, P., Fontenay, M., Hobo, W., Ireland, R., Johansson, U., Loken, M.R., Ogata, K., Orfao, A., Psarra, K., Saft, L., Subira, D., Marvelde, J. Te, Wells, D.A., Velden, V.H. van der, Kern, W., and Loosdrecht, A.A. van de
- Abstract
01 januari 2023, Item does not contain fulltext, Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic syndrome (MDS). MFC can also be applied in the follow-up of MDS patients undergoing treatment. This document summarizes recommendations from the International/European Leukemia Net Working Group for Flow Cytometry in Myelodysplastic Syndromes (ELN iMDS Flow) on the analytical issues in MFC for the diagnostic work-up of MDS. Recommendations for the analysis of several BM cell subsets such as myeloid precursors, maturing granulocytic and monocytic components and erythropoiesis are given. A core set of 17 markers identified as independently related to a cytomorphologic diagnosis of myelodysplasia is suggested as mandatory for MFC evaluation of BM in a patient with cytopenia. A myeloid precursor cell (CD34(+) CD19(-) ) count >3% should be considered immunophenotypically indicative of myelodysplasia. However, MFC results should always be evaluated as part of an integrated hematopathology work-up. Looking forward, several machine-learning-based analytical tools of interest should be applied in parallel to conventional analytical methods to investigate their usefulness in integrated diagnostics, risk stratification, and potentially even in the evaluation of response to therapy, based on MFC data. In addition, compiling large uniform datasets is desirable, as most of the machine-learning-based methods tend to perform better with larger numbers of investigated samples, especially in such a heterogeneous disease as MDS.
- Published
- 2023
5. A novel germline PAX5 single exon deletion in a pediatric patient with precursor B-cell leukemia.
- Author
-
Engelen, N. van, Roest, M., Dijk, F. van, Sonneveld, E., Bladergroen, R., Reijmersdal, S.V. van, Velden, V.H. van der, Hoogeveen, P.G., Kors, W.A., Waanders, E., Jongmans, M.C.J., Kuiper, R.P, Engelen, N. van, Roest, M., Dijk, F. van, Sonneveld, E., Bladergroen, R., Reijmersdal, S.V. van, Velden, V.H. van der, Hoogeveen, P.G., Kors, W.A., Waanders, E., Jongmans, M.C.J., and Kuiper, R.P
- Abstract
01 september 2023, Item does not contain fulltext
- Published
- 2023
6. Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study
- Author
-
Velden, V.H. van der, Brüggemann, M., Cazzaniga, G., Scheijen, B., Tops, B., Trka, J., Pal, K., Hänzelmann, S., Fazio, G., Songia, S., Langerak, A.W., Darzentas, N., Velden, V.H. van der, Brüggemann, M., Cazzaniga, G., Scheijen, B., Tops, B., Trka, J., Pal, K., Hänzelmann, S., Fazio, G., Songia, S., Langerak, A.W., and Darzentas, N.
- Abstract
Contains fulltext : 232927.pdf (Publisher’s version ) (Open Access)
- Published
- 2021
7. Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?
- Author
-
Brooimans, Rik A., Velden, V.H. van der, Boeckx, N., Slomp, J., Preijers, F.W., Marvelde, Jeroen G. te, Kelder, A., Schuurhuis, G.J., Brooimans, Rik A., Velden, V.H. van der, Boeckx, N., Slomp, J., Preijers, F.W., Marvelde, Jeroen G. te, Kelder, A., and Schuurhuis, G.J.
- Abstract
Contains fulltext : 201053.pdf (publisher's version ) (Open Access)
- Published
- 2019
8. Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes
- Author
-
Cremers, E.M., Westers, T.M., Alhan, C., Cali, C., Visser-Wisselaar, H.A., Chitu, D.A., Velden, V.H. van der, Marvelde, J.G. Te, Klein, S.K., Muus, P., Vellenga, E., Greef, G.E. de, Legdeur, M.C., Wijermans, P.W., Stevens-Kroef, M.J.P.L., Silva-Coelho, P., Jansen, J.H., Ossenkoppele, G.J., Loosdrecht, A.A. van de, Cremers, E.M., Westers, T.M., Alhan, C., Cali, C., Visser-Wisselaar, H.A., Chitu, D.A., Velden, V.H. van der, Marvelde, J.G. Te, Klein, S.K., Muus, P., Vellenga, E., Greef, G.E. de, Legdeur, M.C., Wijermans, P.W., Stevens-Kroef, M.J.P.L., Silva-Coelho, P., Jansen, J.H., Ossenkoppele, G.J., and Loosdrecht, A.A. van de
- Abstract
Contains fulltext : 169708.pdf (publisher's version ) (Open Access), Flow cytometric analysis is a recommended tool in the diagnosis of myelodysplastic syndromes. Current flow cytometric approaches evaluate the (im)mature myelo-/monocytic lineage with a median sensitivity and specificity of ~71% and ~93%, respectively. We hypothesized that the addition of erythroid lineage analysis could increase the sensitivity of flow cytometry. Hereto, we validated the analysis of erythroid lineage parameters recommended by the International/European LeukemiaNet Working Group for Flow Cytometry in Myelodysplastic Syndromes, and incorporated this evaluation in currently applied flow cytometric models. One hundred and sixty-seven bone marrow aspirates were analyzed; 106 patients with myelodysplastic syndromes, and 61 cytopenic controls. There was a strong correlation between presence of erythroid aberrancies assessed by flow cytometry and the diagnosis of myelodysplastic syndromes when validating the previously described erythroid evaluation. Furthermore, addition of erythroid aberrancies to two different flow cytometric models led to an increased sensitivity in detecting myelodysplastic syndromes: from 74% to 86% for the addition to the diagnostic score designed by Ogata and colleagues, and from 69% to 80% for the addition to the integrated flow cytometric score for myelodysplastic syndromes, designed by our group. In both models the specificity was unaffected. The high sensitivity and specificity of flow cytometry in the detection of myelodysplastic syndromes illustrates the important value of flow cytometry in a standardized diagnostic approach. The trial is registered at www.trialregister.nl as NTR1825; EudraCT n.: 2008-002195-10.
- Published
- 2017
9. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia
- Author
-
Boer, J.M.A., Steeghs, E.M.P., Marchante, J.R., Boeree, A., Beaudoin, J.J., Beverloo, H.B., Kuiper, R.P., Escherich, G., Velden, V.H. van der, Schoot, C.E. van der, Groot-Kruseman, H.A. de, Pieters, R., Boer, M.L. Den, Boer, J.M.A., Steeghs, E.M.P., Marchante, J.R., Boeree, A., Beaudoin, J.J., Beverloo, H.B., Kuiper, R.P., Escherich, G., Velden, V.H. van der, Schoot, C.E. van der, Groot-Kruseman, H.A. de, Pieters, R., and Boer, M.L. Den
- Abstract
Contains fulltext : 169868.pdf (Publisher’s version ) (Open Access), Approximately 15% of pediatric B cell precursor acute lymphoblastic leukemia (BCP-ALL) is characterized by gene expression similar to that of BCR-ABL1-positive disease and unfavorable prognosis. This BCR-ABL1-like subtype shows a high frequency of B-cell development gene aberrations and tyrosine kinase-activating lesions. To evaluate the clinical significance of tyrosine kinase gene fusions in children with BCP-ALL, we studied the frequency of recently identified tyrosine kinase fusions, associated genetic features, and prognosis in a representative Dutch/German cohort. We identified 14 tyrosine kinase fusions among 77 BCR-ABL1-like cases (18%) and none among 76 non-BCR-ABL1-like B-other cases. Novel exon fusions were identified for RCSD1-ABL2 and TERF2-JAK2. JAK2 mutation was mutually exclusive with tyrosine kinase fusions and only occurred in cases with high CRLF2 expression. The non/late response rate and levels of minimal residual disease in the fusion-positive BCR-ABL1-like group were higher than in the non-BCR-ABL1-like B-others (p<0.01), and also higher, albeit not statistically significant, compared with the fusion-negative BCR-ABL1-like group. The 8-year cumulative incidence of relapse in the fusion-positive BCR-ABL1-like group (35%) was comparable with that in the fusion-negative BCR-ABL1-like group (35%), and worse than in the non-BCR-ABL1-like B-other group (17%, p=0.07). IKZF1 deletions, predominantly other than the dominant-negative isoform and full deletion, co-occurred with tyrosine kinase fusions. This study shows that tyrosine kinase fusion-positive cases are a high-risk subtype of BCP-ALL, which warrants further studies with specific kinase inhibitors to improve outcome.
- Published
- 2017
10. Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences
- Author
-
Waanders, E., Scheijen, B., Jongmans, M.C.J., Venselaar, H., Reijmersdal, S.V. van, Dijk, A.H.A. van, Pastorczak, A., Weren, R.D.A., Schoot, C.E. van der, Vorst, J.M. van de, Sonneveld, E., Hoogerbrugge, N., Velden, V.H. van der, Gruhn, B., Hoogerbrugge, P.M., Dongen, J.J. van, Geurts van Kessel, A.H.M., Leeuwen, F.N. van, Kuiper, R.P., Waanders, E., Scheijen, B., Jongmans, M.C.J., Venselaar, H., Reijmersdal, S.V. van, Dijk, A.H.A. van, Pastorczak, A., Weren, R.D.A., Schoot, C.E. van der, Vorst, J.M. van de, Sonneveld, E., Hoogerbrugge, N., Velden, V.H. van der, Gruhn, B., Hoogerbrugge, P.M., Dongen, J.J. van, Geurts van Kessel, A.H.M., Leeuwen, F.N. van, and Kuiper, R.P.
- Abstract
Contains fulltext : 170242.pdf (publisher's version ) (Closed access)
- Published
- 2017
11. Fifteen years of external quality assessment in leukemia/lymphoma immunophenotyping in the Netherlands and Belgium: A way forward
- Author
-
Preijers, F.W.M.B., Velden, V.H. van der, Preijers, T., Brooimans, R.A., Marijt, E., Homburg, C., Montfort, K. van, and Gratama, J.W.
- Subjects
Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2] - Abstract
Item does not contain fulltext
- Published
- 2016
12. Implementation of flow cytometry in the diagnostic work-up of myelodysplastic syndromes in a multicenter approach
- Author
-
Westers, T.M., Velden, V.H. van der, Alhan, C., Bekkema, R., Bijkerk, A., Brooimans, R.A., Cali, C., Drager, A.M., de Haas, V., Homburg, C., de Jong, A., Kuiper-Kramer, P.E., Leenders, M., Lommerse, I., Marvelde, J.G. Te, van der Molen-Sinke, J.K., Moshaver, B., Mulder, A.B., Preijers, F.W.M.B., Schindhelm, R.K., van der Sluijs, A., van Wering, E.R., Westra, A.H., Loosdrecht, A.A. van de, Working Party on Flow Cytometry in, M.D.S.o.D.S.o.C., Hematology laboratory, Pediatric surgery, Hematology, and CCA - Disease profiling
- Subjects
Male ,Oncology ,BLASTS ,Cancer Research ,medicine.medical_specialty ,Multicenter analysis ,Concordance ,BONE-MARROW ,Cell Separation ,Bioinformatics ,Flow cytometry ,Translational research [ONCOL 3] ,Internal medicine ,hemic and lymphatic diseases ,Diagnosis ,medicine ,MDS ,Humans ,Aged ,Netherlands ,Aged, 80 and over ,PHENOTYPIC FEATURES ,UTILITY ,medicine.diagnostic_test ,Guideline adherence ,business.industry ,Myelodysplastic syndromes ,Hematology ,medicine.disease ,List mode ,CYTOGENETICS ,Work-up ,Standardization ,DIFFERENTIATION ,Multicenter study ,Myelodysplastic Syndromes ,Implementation ,Practice Guidelines as Topic ,CELLS ,Female ,Guideline Adherence ,business ,Pitfalls - Abstract
Flow cytometry (FC) is recognized as an important tool in the diagnosis of myelodysplastic syndromes (MDS) especially when standard criteria fail. A working group within the Dutch Society of Cytometry aimed to implement FC in the diagnostic work-up of MDS. Hereto, guidelines for data acquisition, analysis and interpretation were formulated. Based on discussions on analyses of list mode data files and fresh MDS bone marrow samples and recent literature, the guidelines were modified. Over the years (2005-2011), the concordance between the participating centers increased indicating that the proposed guidelines contributed to a more objective, standardized FC analysis, thereby ratifying the implementation of FC in MDS. (C) 2011 Elsevier Ltd. All rights reserved.
- Published
- 2012
13. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS
- Author
-
Porwit, A., Loosdrecht, A.A. van de, Bettelheim, P., Brodersen, L.E., Burbury, K., Cremers, E., Porta, M.G. Della, Ireland, R., Johansson, U., Matarraz, S., Ogata, K., Orfao, A., Preijers, F.W., Psarra, K., Subirá, D., Valent, P., Velden, V.H. van der, Wells, D., Westers, T.M., Kern, W., Béné, M.C., Porwit, A., Loosdrecht, A.A. van de, Bettelheim, P., Brodersen, L.E., Burbury, K., Cremers, E., Porta, M.G. Della, Ireland, R., Johansson, U., Matarraz, S., Ogata, K., Orfao, A., Preijers, F.W., Psarra, K., Subirá, D., Valent, P., Velden, V.H. van der, Wells, D., Westers, T.M., Kern, W., and Béné, M.C.
- Abstract
Item does not contain fulltext
- Published
- 2014
14. High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
- Author
-
Terwijn, M., Putten, W.L. van, Kelder, A., Velden, V.H. van der, Brooimans, R.A., Pabst, T., Maertens, J., Boeckx, N., Greef, G.E. de, Valk, P.J., Preijers, F.W.M.B., Huijgens, P.C., Dräger, A.M., Schanz, U., Jongen-Lavrecic, M., Biemond, B.J., Passweg, J.R., Gelder, M. van, Wijermans, P., Graux, C., Bargetzi, M., Legdeur, M.C., Kuball, J., Weerdt, O. de, Chalandon, Y., Hess, U., Verdonck, L.F., Gratama, J.W., Oussoren, Y.J., Scholten, W.J., Slomp, J., Snel, A.N., Vekemans, M.C., Löwenberg, B., Ossenkoppele, G.J., Schuurhuis, G.J., Terwijn, M., Putten, W.L. van, Kelder, A., Velden, V.H. van der, Brooimans, R.A., Pabst, T., Maertens, J., Boeckx, N., Greef, G.E. de, Valk, P.J., Preijers, F.W.M.B., Huijgens, P.C., Dräger, A.M., Schanz, U., Jongen-Lavrecic, M., Biemond, B.J., Passweg, J.R., Gelder, M. van, Wijermans, P., Graux, C., Bargetzi, M., Legdeur, M.C., Kuball, J., Weerdt, O. de, Chalandon, Y., Hess, U., Verdonck, L.F., Gratama, J.W., Oussoren, Y.J., Scholten, W.J., Slomp, J., Snel, A.N., Vekemans, M.C., Löwenberg, B., Ossenkoppele, G.J., and Schuurhuis, G.J.
- Abstract
Item does not contain fulltext
- Published
- 2013
15. Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting.
- Author
-
Feller, N., Velden, V.H. van der, Brooimans, R.A., Boeckx, N., Preijers, F.W., Kelder, A., Greef, I. de, Westra, G., Marvelde, J.G. Te, Aerts, P., Wind, H., Leenders, M., Gratama, J.W., Schuurhuis, G.J., Feller, N., Velden, V.H. van der, Brooimans, R.A., Boeckx, N., Preijers, F.W., Kelder, A., Greef, I. de, Westra, G., Marvelde, J.G. Te, Aerts, P., Wind, H., Leenders, M., Gratama, J.W., and Schuurhuis, G.J.
- Abstract
Contains fulltext : 186455.pdf (publisher's version ) (Open Access), Flow-cytometric detection of minimal residual disease (MRD) has proven in several single-institute studies to have an independent prognostic impact. We studied whether this relatively complex approach could be performed in a multicenter clinical setting. Five centers developed common protocols to accurately define leukemia-associated (immuno)phenotypes (LAPs) at diagnosis required to establish MRD during/after treatment. List mode data files were exchanged, and LAPs were designed by each center. One center, with extensive MRD experience, served as the reference center and coordinator. In quarterly meetings, consensus LAPs were defined, with the performance of centers compared with these. In a learning (29 patients) and a test phase (35 patients), a mean of 2.2 aberrancies/patient was detected, and only 1/63 patients (1.6%) had no consensus LAP(s). For the four centers without (extensive) MRD experience, clear improvement could be shown: in the learning phase, 39-63% of all consensus LAPs were missed, resulting in a median 30% of patients (range 21-33%) for whom no consensus LAP was reported; in the test phase, 27-40% missed consensus LAPs, resulting in a median 16% (range 7-18%) of 'missed' patients. The quality of LAPs was extensively described. Immunophenotypic MRD assessment in its current setting needs extensive experience and should be limited to experienced centers.
- Published
- 2013
16. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL
- Author
-
Veer, A. van der, Waanders, E., Pieters, R., Willemse, M.E., Reijmersdal, S.V. van, Russell, L.J., Harrison, C.J., Evans, W.E., Velden, V.H. van der, Hoogerbrugge, P.M., Leeuwen, F van, Escherich, G., Horstmann, M.A., Khankahdani, L. Mohammadi, Rizopoulos, D., Groot-Kruseman, H.A. de, Sonneveld, E., Kuiper, R.P., Boer, M.L. Den, Veer, A. van der, Waanders, E., Pieters, R., Willemse, M.E., Reijmersdal, S.V. van, Russell, L.J., Harrison, C.J., Evans, W.E., Velden, V.H. van der, Hoogerbrugge, P.M., Leeuwen, F van, Escherich, G., Horstmann, M.A., Khankahdani, L. Mohammadi, Rizopoulos, D., Groot-Kruseman, H.A. de, Sonneveld, E., Kuiper, R.P., and Boer, M.L. Den
- Abstract
Item does not contain fulltext, Most relapses in childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL) are not predicted using current prognostic features. Here, we determined the co-occurrence and independent prognostic relevance of 3 recently identified prognostic features: BCR-ABL1-like gene signature, deletions in IKZF1, and high CRLF2 messenger RNA expression (CRLF2-high). These features were determined in 4 trials representing 1128 children with ALL: DCOG ALL-8, ALL9, ALL10, and Cooperative ALL (COALL)-97/03. BCR-ABL1-like, IKZF1-deleted, and CRLF2-high cases constitute 33.7% of BCR-ABL1-negative, MLL wild-type BCP-ALL cases, of which BCR-ABL1-like and IKZF1 deletion (co)occurred most frequently. Higher cumulative incidence of relapse was found for BCR-ABL1-like and IKZF1-deleted, but not CRLF2-high, cases relative to remaining BCP-ALL cases, reflecting the observations in each of the cohorts analyzed separately. No relapses occurred among cases with CRLF2-high as single feature, whereas 62.9% of all relapses in BCR-ABL1-negative, MLL wild-type BCP-ALL occurred in cases with BCR-ABL1-like signature and/or IKZF1 deletion. Both the BCR-ABL1-like signature and IKZF1 deletions were prognostic features independent of conventional prognostic markers in a multivariate model, and both remained prognostic among cases with intermediate minimal residual disease. The BCR-ABL1-like signature and an IKZF1 deletion, but not CRLF2-high, are prognostic factors and are clinically of importance to identify high-risk patients who require more intensive and/or alternative therapies.
- Published
- 2013
17. Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group
- Author
-
Loosdrecht, A.A. van de, Ireland, R., Kern, W., Della Porta, M.G., Alhan, C., Balleisen, J.S., Bettelheim, P., Bowen, D.T., Burbury, K., Eidenschink, L., Cazzola, M., Chu, S.S., Cullen, M., Cutler, J.A., Drager, A.M., Feuillard, J., Fenaux, P., Font, P., Germing, U., Haase, D., Hellstrom-Lindberg, E., Johansson, U., Kordasti, S., Loken, M.R., Malcovati, L., Marvelde, J.G. Te, Matarraz, S., Milne, T., Moshaver, B., Mufti, G.J., Nikolova, V., Ogata, K., Oelschlaegel, U., Orfao, A., Ossenkoppele, G.J., Porwit, A., Platzbecker, U., Preijers, F.W.M.B., Psarra, K., Richards, S.J., Subira, D., Seymour, J.F., Tindell, V., Vallespi, T., Valent, P., Velden, V.H. van der, Wells, D.A., Witte, T.J.M. de, Zettl, F., Bene, M.C., Westers, T.M., Loosdrecht, A.A. van de, Ireland, R., Kern, W., Della Porta, M.G., Alhan, C., Balleisen, J.S., Bettelheim, P., Bowen, D.T., Burbury, K., Eidenschink, L., Cazzola, M., Chu, S.S., Cullen, M., Cutler, J.A., Drager, A.M., Feuillard, J., Fenaux, P., Font, P., Germing, U., Haase, D., Hellstrom-Lindberg, E., Johansson, U., Kordasti, S., Loken, M.R., Malcovati, L., Marvelde, J.G. Te, Matarraz, S., Milne, T., Moshaver, B., Mufti, G.J., Nikolova, V., Ogata, K., Oelschlaegel, U., Orfao, A., Ossenkoppele, G.J., Porwit, A., Platzbecker, U., Preijers, F.W.M.B., Psarra, K., Richards, S.J., Subira, D., Seymour, J.F., Tindell, V., Vallespi, T., Valent, P., Velden, V.H. van der, Wells, D.A., Witte, T.J.M. de, Zettl, F., Bene, M.C., and Westers, T.M.
- Abstract
Item does not contain fulltext, An international working group within the European LeukemiaNet gathered, aiming to determine the role of flow cytometry (FC) in myelodysplastic syndromes (MDS). It was agreed that FC has a substantial application in disease characterization, diagnosis and prognosis. FC may also be useful in predicting treatment responses and monitoring novel and standard therapeutic regimens. In this article the rationale is discussed that flow cytometry should be integrated as a part of diagnostic and prognostic scoring systems in MDS.
- Published
- 2013
18. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
- Author
-
Marshall, G.M., Pozza, L. Dalla, Sutton, R., Ng, A., Groot-Kruseman, H.A. de, Velden, V.H. van der, Venn, N.C., Berg, H. van den, Bont, E.S. de, rten Egeler, R. Maa, Hoogerbrugge, P.M., Kaspers, G.J.L., Bierings, M.B., Schoot, E. van der, Dongen, J. Van, Law, T., Cross, S., Mueller, H., Haas, V. de, Haber, M., Revesz, T., Alvaro, F., Suppiah, R., Norris, M.D., Pieters, R., Marshall, G.M., Pozza, L. Dalla, Sutton, R., Ng, A., Groot-Kruseman, H.A. de, Velden, V.H. van der, Venn, N.C., Berg, H. van den, Bont, E.S. de, rten Egeler, R. Maa, Hoogerbrugge, P.M., Kaspers, G.J.L., Bierings, M.B., Schoot, E. van der, Dongen, J. Van, Law, T., Cross, S., Mueller, H., Haas, V. de, Haber, M., Revesz, T., Alvaro, F., Suppiah, R., Norris, M.D., and Pieters, R.
- Abstract
Item does not contain fulltext, Children with acute lymphoblastic leukemia (ALL) and high minimal residual disease (MRD) levels after initial chemotherapy have a poor clinical outcome. In this prospective, single arm, Phase 2 trial, 111 Dutch and Australian children aged 1-18 years with newly diagnosed, t(9;22)-negative ALL, were identified among 1041 consecutively enrolled patients as high risk (HR) based on clinical features or high MRD. The HR cohort received the AIEOP-BFM (Associazione Italiana di Ematologia ed Oncologia Pediatrica (Italy)-Berlin-Frankfurt-Munster ALL Study Group) 2000 ALL Protocol I, then three novel HR chemotherapy blocks, followed by allogeneic transplant or chemotherapy. Of the 111 HR patients, 91 began HR treatment blocks, while 79 completed the protocol. There were 3 remission failures, 12 relapses, 7 toxic deaths in remission and 10 patients who changed protocol due to toxicity or clinician/parent preference. For the 111 HR patients, 5-year event-free survival (EFS) was 66.8% (+/-5.5) and overall survival (OS) was 75.6% (+/-4.3). The 30 patients treated as HR solely on the basis of high MRD levels had a 5-year EFS of 63% (+/-9.4%). All patients experienced grade 3 or 4 toxicities during HR block therapy. Although cure rates were improved compared with previous studies, high treatment toxicity suggested that novel agents are needed to achieve further improvement.
- Published
- 2013
19. Implementation of flow cytometry in the diagnostic work-up of myelodysplastic syndromes in a multicenter approach: report from the Dutch Working Party on Flow Cytometry in MDS
- Author
-
Westers, T.M., Velden, V.H. van der, Alhan, C., Bekkema, R., Bijkerk, A., Brooimans, R.A., Cali, C., Drager, A.M., de Haas, V., Homburg, C., de Jong, A., Kuiper-Kramer, P.E., Leenders, M., Lommerse, I., Marvelde, J.G. Te, van der Molen-Sinke, J.K., Moshaver, B., Mulder, A.B., Preijers, F.W.M.B., Schindhelm, R.K., van der Sluijs, A., van Wering, E.R., Westra, A.H., Loosdrecht, A.A. van de, Working Party on Flow Cytometry in, M.D.S.o.D.S.o.C., Westers, T.M., Velden, V.H. van der, Alhan, C., Bekkema, R., Bijkerk, A., Brooimans, R.A., Cali, C., Drager, A.M., de Haas, V., Homburg, C., de Jong, A., Kuiper-Kramer, P.E., Leenders, M., Lommerse, I., Marvelde, J.G. Te, van der Molen-Sinke, J.K., Moshaver, B., Mulder, A.B., Preijers, F.W.M.B., Schindhelm, R.K., van der Sluijs, A., van Wering, E.R., Westra, A.H., Loosdrecht, A.A. van de, and Working Party on Flow Cytometry in, M.D.S.o.D.S.o.C.
- Abstract
Item does not contain fulltext, Flow cytometry (FC) is recognized as an important tool in the diagnosis of myelodysplastic syndromes (MDS) especially when standard criteria fail. A working group within the Dutch Society of Cytometry aimed to implement FC in the diagnostic work-up of MDS. Hereto, guidelines for data acquisition, analysis and interpretation were formulated. Based on discussions on analyses of list mode data files and fresh MDS bone marrow samples and recent literature, the guidelines were modified. Over the years (2005-2011), the concordance between the participating centers increased indicating that the proposed guidelines contributed to a more objective, standardized FC analysis, thereby ratifying the implementation of FC in MDS.
- Published
- 2012
20. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group.
- Author
-
Westers, T.M., Ireland, R., Kern, W., Alhan, C., Balleisen, J.S., Bettelheim, P., Burbury, K., Cullen, M., Cutler, J.A., Porta, M.G. Della, Drager, A.M., Feuillard, J., Font, P., Germing, U., Haase, D., Johansson, U., Kordasti, S., Loken, M.R., Malcovati, L., Marvelde, J.G. Te, Matarraz, S., Milne, T., Moshaver, B., Mufti, G.J., Ogata, K., Orfao, A., Porwit, A., Psarra, K., Richards, S.J., Subira, D., Tindell, V., Vallespi, T., Valent, P., Velden, V.H. van der, Witte, T.J.M. de, Wells, D.A., Zettl, F., Bene, M.C., Loosdrecht, A.A. van de, Westers, T.M., Ireland, R., Kern, W., Alhan, C., Balleisen, J.S., Bettelheim, P., Burbury, K., Cullen, M., Cutler, J.A., Porta, M.G. Della, Drager, A.M., Feuillard, J., Font, P., Germing, U., Haase, D., Johansson, U., Kordasti, S., Loken, M.R., Malcovati, L., Marvelde, J.G. Te, Matarraz, S., Milne, T., Moshaver, B., Mufti, G.J., Ogata, K., Orfao, A., Porwit, A., Psarra, K., Richards, S.J., Subira, D., Tindell, V., Vallespi, T., Valent, P., Velden, V.H. van der, Witte, T.J.M. de, Wells, D.A., Zettl, F., Bene, M.C., and Loosdrecht, A.A. van de
- Abstract
1 juli 2012, Item does not contain fulltext, Flow cytometry (FC) is increasingly recognized as an important tool in the diagnosis and prognosis of myelodysplastic syndromes (MDS). However, validation of current assays and agreement upon the techniques are prerequisites for its widespread acceptance and application in clinical practice. Therefore, a working group was initiated (Amsterdam, 2008) to discuss and propose standards for FC in MDS. In 2009 and 2010, representatives from 23, mainly European, institutes participated in the second and third European LeukemiaNet (ELN) MDS workshops. In the present report, minimal requirements to analyze dysplasia are refined. The proposed core markers should enable a categorization of FC results in cytopenic patients as 'normal', 'suggestive of', or 'diagnostic of' MDS. An FC report should include a description of validated FC abnormalities such as aberrant marker expression on myeloid progenitors and, furthermore, dysgranulopoiesis and/or dysmonocytopoiesis, if at least two abnormalities are evidenced. The working group is dedicated to initiate further studies to establish robust diagnostic and prognostic FC panels in MDS. An ultimate goal is to refine and improve diagnosis and prognostic scoring systems. Finally, the working group stresses that FC should be part of an integrated diagnosis rather than a separate technique.
- Published
- 2012
21. High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia.
- Author
-
Luesink, M., Hollink, I.H., Velden, V.H. van der, Knops, R.H., Boezeman, J.B.M., Haas, V. de, Trka, J., Baruchel, A., Reinhardt, D., Reijden, B.A. van der, Heuvel-Eibrink, M.M. van den, Zwaan, C.M., Jansen, J.H., Luesink, M., Hollink, I.H., Velden, V.H. van der, Knops, R.H., Boezeman, J.B.M., Haas, V. de, Trka, J., Baruchel, A., Reinhardt, D., Reijden, B.A. van der, Heuvel-Eibrink, M.M. van den, Zwaan, C.M., and Jansen, J.H.
- Abstract
Item does not contain fulltext, In acute myeloid leukemia (AML), aberrant expression and mutations of transcription factors have been correlated with disease outcome. In the present study, we performed expression and mutation screening of GATA2, which is an essential transcription factor for regulation of myeloid lineage determination, in de novo pediatric AML patients. GATA2 mutations were detected in 5 of 230 patients, representing a frequency of 2.2% overall and 9.8% in cytogenetically normal AML. GATA2 expression analysis demonstrated that in 155 of 237 diagnostic samples (65%), GATA2 expression was higher than in normal BM. In complete remission, normalization of GATA2 expression was observed, whereas GATA2 expression levels stayed high in patients with resistant disease. High GATA2 expression at diagnosis was an independent poor prognostic factor for overall survival (hazard ratio [HR] = 1.7, P = .045), event-free survival (HR = 2.1, P = .002), and disease-free survival (HR = 2.3, P = .004). The prognostic impact of GATA2 was particularly evident in specific AML subgroups. In patients with French-American-British M5 morphology, inv(16), or high WT1 expression, significant differences in survival were observed between patients with high versus normal GATA2 expression. We conclude that high GATA2 expression is a novel poor prognostic marker in pediatric AML, which may contribute to better risk-group stratification and risk-adapted therapy in the future.
- Published
- 2012
22. Highly sensitive MRD tests for ALL based on the IKZF1 Delta3-6 microdeletion
- Author
-
Venn, N.C., Velden, V.H. van der, de Bie, M., Waanders, E., Giles, J.E., Law, T., Kuiper, R.P., de Haas, V., Mullighan, C.G., Haber, M., Marshall, G.M., Md, N., van Dongen, J.J., Sutton, R., Venn, N.C., Velden, V.H. van der, de Bie, M., Waanders, E., Giles, J.E., Law, T., Kuiper, R.P., de Haas, V., Mullighan, C.G., Haber, M., Marshall, G.M., Md, N., van Dongen, J.J., and Sutton, R.
- Abstract
Item does not contain fulltext
- Published
- 2012
23. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia
- Author
-
Waanders, E., Velden, V.H. van der, Schoot, C.E. van der, Leeuwen, F.N. van, Reijmersdal, S.V. van, Haas, V. de, Veerman, A.J.P., Geurts van Kessel, A.H.M., Hoogerbrugge, P.M., Kuiper, R.P., Dongen, J.J. van, Waanders, E., Velden, V.H. van der, Schoot, C.E. van der, Leeuwen, F.N. van, Reijmersdal, S.V. van, Haas, V. de, Veerman, A.J.P., Geurts van Kessel, A.H.M., Hoogerbrugge, P.M., Kuiper, R.P., and Dongen, J.J. van
- Abstract
Item does not contain fulltext, Response to therapy as determined by minimal residual disease (MRD) is currently used for stratification in treatment protocols for pediatric acute lymphoblastic leukemia (ALL). However, the large MRD-based medium risk group (MRD-M; 50-60% of the patients) harbors many relapses. We analyzed MRD in 131 uniformly treated precursor-B-ALL patients and evaluated whether combined MRD and IKZF1 (Ikaros zinc finger-1) alteration status can improve risk stratification. We confirmed the strong prognostic significance of MRD classification, which was independent of IKZF1 alterations. Notably, 8 of the 11 relapsed cases in the large MRD-M group (n=81; 62%) harbored an IKZF1 alteration. Integration of both MRD and IKZF1 status resulted in a favorable outcome group (n=104; 5 relapses) and a poor outcome group (n=27; 19 relapses), and showed a stronger prognostic value than each of the established risk factors alone (hazard ratio (95%CI): 24.98 (8.29-75.31)). Importantly, whereas MRD and IKZF1 status alone identified only 46 and 54% of the relapses, respectively, their integrated use allowed prediction of 79% of all the relapses with 93% specificity. Because of the unprecedented sensitivity in upfront relapse prediction, the combined parameters have high potential for future risk stratification, particularly for patients originally classified as non-high risk, such as the large group of MRD-M patients.
- Published
- 2011
24. Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition
- Author
-
Szczepanski, T., Velden, V.H. van der, Waanders, E., Kuiper, R.P., Vlierberghe, P. Van, Gruhn, B., Eckert, C., Panzer-Grumayer, R., Basso, G., Cave, H., Stadt, U.Z., Campana, D., Schrauder, A., Sutton, R., Wering, E. van, Meijerink, J.P.P., Dongen, J.J. van, Szczepanski, T., Velden, V.H. van der, Waanders, E., Kuiper, R.P., Vlierberghe, P. Van, Gruhn, B., Eckert, C., Panzer-Grumayer, R., Basso, G., Cave, H., Stadt, U.Z., Campana, D., Schrauder, A., Sutton, R., Wering, E. van, Meijerink, J.P.P., and Dongen, J.J. van
- Abstract
Item does not contain fulltext, PURPOSE: Relapse of childhood T-cell acute lymphoblastic leukemia (T-ALL) often occurs during treatment, but in some cases, leukemia re-emerges off therapy. On the basis of previous analyses of T-cell receptor (TCR) gene rearrangement patterns, we hypothesized that some late recurrences of T-ALL might in fact represent second leukemias. PATIENTS AND METHODS: In 22 patients with T-ALL who had late relapses (at least 2.5 years from diagnosis), we studied TCR gene rearrangement status at first and second presentation, NOTCH1 gene mutations, and the presence of the SIL-TAL1 gene fusion. We performed genome-wide copy number and homozygosity analysis by using oligonucleotide- and single nucleotide polymorphism (SNP) -based arrays. RESULTS: We found evidence of a common clonal origin between diagnosis and relapse in 14 patients (64%). This was based on concordant TCR gene rearrangements (12 patients) or concordant genetic aberrations, as revealed by genome-wide copy number analysis (two patients). In the remaining eight patients (36%), TCR gene rearrangement sequences had completely changed between diagnosis and relapse, and gene copy number analysis showed markedly different patterns of genomic aberrations, suggesting a second T-ALL rather than a resurgence of the original clone. Moreover, NOTCH1 mutation patterns were different at diagnosis and relapse in five of these eight patients. In one patient with a second T-ALL, SNP analysis revealed a germline del(11)(p12;p13), a known recurrent aberration in T-ALL. CONCLUSION: More than one third of late T-ALL recurrences are, in fact, second leukemias. Germline genetic abnormalities might contribute to the susceptibility of some patients to develop T-ALL.
- Published
- 2011
25. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol.
- Author
-
Velden, V.H. van der, Sluijs-Geling, A. van der, Gibson, B.E., Marvelde, J.G. Te, Hoogeveen, P.G., Hop, W.C.J., Wheatley, K., Bierings, M.B., Schuurhuis, G.J., Graaf, S.S.N. de, Wering, E.R. van, Dongen, J.J.A.M. van, Velden, V.H. van der, Sluijs-Geling, A. van der, Gibson, B.E., Marvelde, J.G. Te, Hoogeveen, P.G., Hop, W.C.J., Wheatley, K., Bierings, M.B., Schuurhuis, G.J., Graaf, S.S.N. de, Wering, E.R. van, and Dongen, J.J.A.M. van
- Abstract
1 september 2010, Item does not contain fulltext, Analysis of minimal residual disease (MRD) in childhood acute myeloid leukemia (AML) may predict for clinical outcome. MRD levels were assessed by flowcytometric immunophenotyping in 94 children with AML enrolled into a single trial (United Kingdom Medical Research Council AML12 and similar Dutch Childhood Oncology Group ANLL97). An aberrant immunophenotype could be detected in 94% of patients. MRD levels after the first course of chemotherapy predicted for clinical outcome: 3-year relapse-free survival was 85%+/-8% (s.e.) for MRD-negative patients (MRD<0.1%), 64%+/-10% for MRD-low-positive patients (0.1%
or=0.5%; P<0.001), whereas overall survival was 95%+/-5%, 70%+/-10% and 40%+/-13%, respectively, (P<0.001). Multivariate analysis allowing for age, karyotype, FLT3-internal tandem duplications and white blood cell count at diagnosis showed that MRD after the first course of chemotherapy was an independent prognostic factor. Although comparison of paired diagnosis-relapse samples (n=23) showed immunophenotypic shifts in 91% of cases, this did not hamper MRD analysis. In conclusion, flowcytometric MRD detection is possible in children with AML. The level of MRD after the first course of chemotherapy provides prognostic information that may be used to guide therapy. - Published
- 2010
26. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.
- Author
-
Kuiper, R.P., Waanders, E., Velden, V.H. van der, Reijmersdal, S.V. van, Venkatachalam, R., Scheijen, B., Sonneveld, E., Dongen, J.J.A.M. van, Veerman, A.J.P., Leeuwen, F.N. van, Geurts van Kessel, A.H.M., Hoogerbrugge, P.M., Kuiper, R.P., Waanders, E., Velden, V.H. van der, Reijmersdal, S.V. van, Venkatachalam, R., Scheijen, B., Sonneveld, E., Dongen, J.J.A.M. van, Veerman, A.J.P., Leeuwen, F.N. van, Geurts van Kessel, A.H.M., and Hoogerbrugge, P.M.
- Abstract
01 juli 2010, Contains fulltext : 88251.pdf (publisher's version ) (Closed access), Relapse is the most common cause of treatment failure in pediatric acute lymphoblastic leukemia (ALL) and is often difficult to predict. To explore the prognostic impact of recurrent DNA copy number abnormalities on relapse, we performed high-resolution genomic profiling of 34 paired diagnosis and relapse ALL samples. Recurrent lesions detected at diagnosis, including PAX5, CDKN2A and EBF1, were frequently absent at relapse, indicating that they represent secondary events that may be absent in the relapse-prone therapy-resistant progenitor cell. In contrast, deletions and nonsense mutations in IKZF1 (IKAROS) were highly enriched and consistently preserved at the time of relapse. A targeted copy number screen in an unselected cohort of 131 precursor B-ALL cases, enrolled in the dexamethasone-based Dutch Childhood Oncology Group treatment protocol ALL9, revealed that IKZF1 deletions are significantly associated with poor relapse-free and overall survival rates. Separate analysis of ALL9-treatment subgroups revealed that non-high-risk (NHR) patients with IKZF1 deletions exhibited a approximately 12-fold higher relative relapse rate than those without IKZF1 deletions. Consequently, IKZF1 deletion status allowed the prospective identification of 53% of the relapse-prone NHR-classified patients within this subgroup and, therefore, serves as one of the strongest predictors of relapse at the time of diagnosis with high potential for future risk stratification.
- Published
- 2010
27. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
- Author
-
Cilloni, D., Renneville, A., Hermitte, F., Hills, R.K., Daly, S., Jovanovic, J.V., Gottardi, E., Fava, M., Schnittger, S., Weiss, T., Izzo, B., Nomdedeu, J., Heijden, A. van der, Reijden, B.A. van der, Jansen, J.H., Velden, V.H. van der, Ommen, H., Preudhomme, C., Saglio, G., Grimwade, D., Cilloni, D., Renneville, A., Hermitte, F., Hills, R.K., Daly, S., Jovanovic, J.V., Gottardi, E., Fava, M., Schnittger, S., Weiss, T., Izzo, B., Nomdedeu, J., Heijden, A. van der, Reijden, B.A. van der, Jansen, J.H., Velden, V.H. van der, Ommen, H., Preudhomme, C., Saglio, G., and Grimwade, D.
- Abstract
Item does not contain fulltext, PURPOSE: Risk stratification in acute myeloid leukemia (AML) is currently based on pretreatment characteristics. It remains to be established whether relapse risk can be better predicted through assessment of minimal residual disease (MRD). One proposed marker is the Wilms tumor gene WT1, which is overexpressed in most patients with AML, thus providing a putative target for immunotherapy, although in the absence of a standardized assay, its utility for MRD monitoring remains controversial. PATIENTS AND METHODS: Nine published and in-house real-time quantitative polymerase chain reaction WT1 assays were systematically evaluated within the European LeukemiaNet; the best-performing assay was applied to diagnostic AML samples (n = 620), follow-up samples from 129 patients treated with intensive combination chemotherapy, and 204 normal peripheral blood (PB) and bone marrow (BM) controls. RESULTS: Considering relative levels of expression detected in normal PB and BM, WT1 was sufficiently overexpressed to discriminate > or = 2-log reduction in transcripts in 46% and 13% of AML patients, according to the respective follow-up sample source. In this informative group, greater WT1 transcript reduction after induction predicted reduced relapse risk (hazard ratio, 0.54 per log reduction; 95% CI, 0.36 to 0.83; P = .004) that remained significant when adjusted for age, WBC count, and cytogenetics. Failure to reduce WT1 transcripts below the threshold limits defined in normal controls by the end of consolidation also predicted increased relapse risk (P = .004). CONCLUSION: Application of a standardized WT1 assay provides independent prognostic information in AML, lending support to incorporation of early assessment of MRD to develop more robust risk scores, to enhance risk stratification, and to identify patients who may benefit from allogeneic transplantation.
- Published
- 2009
28. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.
- Author
-
Loosdrecht, A.A. van de, Alhan, C., Bene, M.C., Porta, M.G. Della, Drager, A.M., Feuillard, J., Font, P., Germing, U., Haase, D., Homburg, C.H., Ireland, R., Jansen, J.H., Kern, W., Malcovati, L., Marvelde, J.G. Te, Mufti, G.J., Ogata, K., Orfao, A., Ossenkoppele, G.J., Porwit, A., Preijers, F.W.M.B., Richards, S.J., Schuurhuis, G.J., Subira, D., Valent, P., Velden, V.H. van der, Vyas, P., Westra, A.H., Witte, T.J.M. de, Wells, D.A., Loken, M.R., Westers, T.M., Loosdrecht, A.A. van de, Alhan, C., Bene, M.C., Porta, M.G. Della, Drager, A.M., Feuillard, J., Font, P., Germing, U., Haase, D., Homburg, C.H., Ireland, R., Jansen, J.H., Kern, W., Malcovati, L., Marvelde, J.G. Te, Mufti, G.J., Ogata, K., Orfao, A., Ossenkoppele, G.J., Porwit, A., Preijers, F.W.M.B., Richards, S.J., Schuurhuis, G.J., Subira, D., Valent, P., Velden, V.H. van der, Vyas, P., Westra, A.H., Witte, T.J.M. de, Wells, D.A., Loken, M.R., and Westers, T.M.
- Abstract
Contains fulltext : 81483.pdf (publisher's version ) (Open Access), The myelodysplastic syndromes are a group of clonal hematopoietic stem cell diseases characterized by cytopenia(s), dysplasia in one or more cell lineages and increased risk of evolution to acute myeloid leukemia (AML). Recent advances in immunophenotyping of hematopoietic progenitor and maturing cells in dysplastic bone marrow point to a useful role for multiparameter flow cytometry (FCM) in the diagnosis and prognostication of myelodysplastic syndromes. In March 2008, representatives from 18 European institutes participated in a European LeukemiaNet (ELN) workshop held in Amsterdam as a first step towards standardization of FCM in myelodysplastic syndromes. Consensus was reached regarding standard methods for cell sampling, handling and processing. The group also defined minimal combinations of antibodies to analyze aberrant immunophenotypes and thus dysplasia. Examples are altered numbers of CD34(+) precursors, aberrant expression of markers on myeloblasts, maturing myeloid cells, monocytes or erythroid precursors and the expression of lineage infidelity markers. When applied in practice, aberrant FCM patterns correlate well with morphology, the subclassification of myelodysplastic syndromes, and prognostic scoring systems. However, the group also concluded that despite strong evidence for an impact of FCM in myelodysplastic syndromes, further (prospective) validation of markers and immunophenotypic patterns are required against control patient groups as well as further standardization in multi-center studies. Standardization of FCM in myelodysplastic syndromes may thus contribute to improved diagnosis and prognostication of myelodysplastic syndromes in the future.
- Published
- 2009
29. Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia.
- Author
-
Velden, V.H. van der, Joosten, S.A., Willemse, M.P., Wering, E.R. van, Lankester, A.W., Dongen, J.J.M. van, Hoogerbrugge, P.M., Velden, V.H. van der, Joosten, S.A., Willemse, M.P., Wering, E.R. van, Lankester, A.W., Dongen, J.J.M. van, and Hoogerbrugge, P.M.
- Abstract
Item does not contain fulltext
- Published
- 2001
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.